A

Aileron Therapeutics Inc
NASDAQ:ALRN

Watchlist Manager
Aileron Therapeutics Inc
NASDAQ:ALRN
Watchlist
Price: 2.47 USD -4.26% Market Closed
Market Cap: 53.5m USD
Have any thoughts about
Aileron Therapeutics Inc?
Write Note

Intrinsic Value

ALRN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ALRN stock under the Base Case scenario is 0.81 USD. Compared to the current market price of 2.47 USD, Aileron Therapeutics Inc is Overvalued by 67%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALRN Intrinsic Value
0.81 USD
Overvaluation 67%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Aileron Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ALRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ALRN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Aileron Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Aileron Therapeutics Inc

Provide an overview of the primary business activities
of Aileron Therapeutics Inc.

What unique competitive advantages
does Aileron Therapeutics Inc hold over its rivals?

What risks and challenges
does Aileron Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Aileron Therapeutics Inc recently?

Summarize the latest earnings call
of Aileron Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aileron Therapeutics Inc.

Provide P/S
for Aileron Therapeutics Inc.

Provide P/E
for Aileron Therapeutics Inc.

Provide P/OCF
for Aileron Therapeutics Inc.

Provide P/FCFE
for Aileron Therapeutics Inc.

Provide P/B
for Aileron Therapeutics Inc.

Provide EV/S
for Aileron Therapeutics Inc.

Provide EV/GP
for Aileron Therapeutics Inc.

Provide EV/EBITDA
for Aileron Therapeutics Inc.

Provide EV/EBIT
for Aileron Therapeutics Inc.

Provide EV/OCF
for Aileron Therapeutics Inc.

Provide EV/FCFF
for Aileron Therapeutics Inc.

Provide EV/IC
for Aileron Therapeutics Inc.

Show me price targets
for Aileron Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aileron Therapeutics Inc?

How accurate were the past Revenue estimates
for Aileron Therapeutics Inc?

What are the Net Income projections
for Aileron Therapeutics Inc?

How accurate were the past Net Income estimates
for Aileron Therapeutics Inc?

What are the EPS projections
for Aileron Therapeutics Inc?

How accurate were the past EPS estimates
for Aileron Therapeutics Inc?

What are the EBIT projections
for Aileron Therapeutics Inc?

How accurate were the past EBIT estimates
for Aileron Therapeutics Inc?

Compare the revenue forecasts
for Aileron Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aileron Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aileron Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aileron Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aileron Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aileron Therapeutics Inc with its peers.

Analyze the financial leverage
of Aileron Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aileron Therapeutics Inc.

Provide ROE
for Aileron Therapeutics Inc.

Provide ROA
for Aileron Therapeutics Inc.

Provide ROIC
for Aileron Therapeutics Inc.

Provide ROCE
for Aileron Therapeutics Inc.

Provide Gross Margin
for Aileron Therapeutics Inc.

Provide Operating Margin
for Aileron Therapeutics Inc.

Provide Net Margin
for Aileron Therapeutics Inc.

Provide FCF Margin
for Aileron Therapeutics Inc.

Show all solvency ratios
for Aileron Therapeutics Inc.

Provide D/E Ratio
for Aileron Therapeutics Inc.

Provide D/A Ratio
for Aileron Therapeutics Inc.

Provide Interest Coverage Ratio
for Aileron Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aileron Therapeutics Inc.

Provide Quick Ratio
for Aileron Therapeutics Inc.

Provide Current Ratio
for Aileron Therapeutics Inc.

Provide Cash Ratio
for Aileron Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aileron Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aileron Therapeutics Inc?

What is the current Free Cash Flow
of Aileron Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aileron Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aileron Therapeutics Inc

Current Assets 18.7m
Cash & Short-Term Investments 17.7m
Other Current Assets 1m
Non-Current Assets 85.5m
PP&E 1k
Intangibles 85.5m
Other Non-Current Assets 2k
Current Liabilities 5.7m
Accounts Payable 1.1m
Accrued Liabilities 4.6m
Non-Current Liabilities 3.3m
Other Non-Current Liabilities 3.3m
Efficiency

Earnings Waterfall
Aileron Therapeutics Inc

Revenue
0 USD
Operating Expenses
-29.6m USD
Operating Income
-29.6m USD
Other Expenses
376k USD
Net Income
-29.2m USD

Free Cash Flow Analysis
Aileron Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ALRN Profitability Score
Profitability Due Diligence

Aileron Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

45/100
Profitability
Score

Aileron Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

ALRN Solvency Score
Solvency Due Diligence

Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALRN Price Targets Summary
Aileron Therapeutics Inc

Wall Street analysts forecast ALRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALRN is 13.26 USD with a low forecast of 7.07 USD and a high forecast of 19.95 USD.

Lowest
Price Target
7.07 USD
186% Upside
Average
Price Target
13.26 USD
437% Upside
Highest
Price Target
19.95 USD
708% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALRN?

Click here to dive deeper.

Dividends

Aileron Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ALRN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Aileron Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

53.5m USD

Dividend Yield

0%

Description

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2017-06-29. The firm is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. The company is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. The company stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.

Contact

MASSACHUSETTS
Boston
285 Summer Street, Unit 101
+16179950900.0
www.aileronrx.com

IPO

2017-06-29

Employees

9

Officers

CEO, President & Director
Dr. James Brian Windsor Ph.D.
Interim CFO & Principal Accounting Officer
Mr. Timothy M. Cunningham CPA, M.B.A.

See Also

Discover More
What is the Intrinsic Value of one ALRN stock?

The intrinsic value of one ALRN stock under the Base Case scenario is 0.81 USD.

Is ALRN stock undervalued or overvalued?

Compared to the current market price of 2.47 USD, Aileron Therapeutics Inc is Overvalued by 67%.

Back to Top